Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

c2crusher 36 posts  |  Last Activity: May 21, 2016 5:28 PM Member since: Aug 31, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Barron's article

    by onzoman2000 May 21, 2016 11:41 AM
    c2crusher c2crusher May 21, 2016 5:28 PM Flag

    Yes, and from the same article,

    "Frost is probably one of the smartest men on the planet,” adds Honig. “This world needs a lot more people like him.”

    Honig then challenged me to a pair trade. He’d go short Apple (AAPL) and long Opko -- a penny-stock promoter’s epic challenge to the mega-cap gods.

    “You don’t bet against Phil Frost,” Honig says.

    Crusher.

  • Reply to

    Zika spreading to other countries

    by c2crusher May 20, 2016 1:26 PM
    c2crusher c2crusher May 20, 2016 2:01 PM Flag

    Is Ray and team working behind the scenes and will Cocp be part of the Zika solution?
    Ray is very well connected and it wouldn't surprise me to see that their structure based design tech platform being used to target the virus.
    Will their Dungue program some how factor in to all this?
    Obama is throwing a lot of money at it. This virus more serious than most think.
    "We are pleased to demonstrate the ability of our structure-based drug design technology to identify a viable clinical candidate and the Company's ability to advance a drug from a concept into the clinic."

  • Reply to

    Zika spreading to other countries

    by c2crusher May 20, 2016 1:26 PM
    c2crusher c2crusher May 20, 2016 1:32 PM Flag

    What do we need to know about viruses?
    April 7/2016
    A bit of good news on the Zika front is that a vaccine for dengue has recently performed quite well in a small study in human volunteers. Dengue is part of the same family as Zika, and the techniques used to develop the dengue vaccine may work for a Zika vaccine as well. Both dengue and Zika are transmitted by the same mosquito, Aedes aegypti. Dengue is currently the most common mosquito-transmitted disease in the world, infecting about 400 million people world-wide. Fortunately (as with Zika) most recover and are immune to the specific dengue serotype they were infected with; however, if they should happen to be infected with a different dengue serotype, they may develop serious and potentially fatal hemorrhagic fevers.
    Cocp working on the right programs at the right time.
    Should be a very exciting time for drug discovery for innovative, best in class companies like Cocrystal trailblazing the future of first in class antivirals.

  • Reply to

    Zika spreading to other countries

    by c2crusher May 20, 2016 1:26 PM
    c2crusher c2crusher May 20, 2016 1:29 PM Flag

    Federal officials say they're taking $500 million aimed at fighting Ebola to use against Zika instead because Congress won't approve new funding.

    They said the risk of Zika is too serious to wait for Congress to appropriate the $1.9 billion the Obama administration has asked for, so they are moving $589 from other projects for immediate Zika use. But they said they'd continue urging Congress to OK the full amount.

  • The Zika virus that has caused birth abnormalities and neurological defects in South America has been identified in Africa for the first time, raising fears it could soon become a global concern, the World Health Organisation said on Friday.

    Matshidiso Moeti, the WHO’s Africa director, said that research conducted on samples of a virus that is thought to have affected more than 7,000 in Cape Verde had shown a match to the one circulating in Brazil and other Latin American countries.

  • Reply to

    COCP financials – part 2

    by onzoman2000 May 16, 2016 10:06 AM
    c2crusher c2crusher May 17, 2016 2:33 PM Flag

    The world unfortunately is filled with bozomen like you.
    Usually ignoramuses or fraud artists.
    In your case I believe both apply.
    GLTA

  • Reply to

    COCP "Overview"

    by onzoman2000 May 17, 2016 9:30 AM
    c2crusher c2crusher May 17, 2016 11:55 AM Flag

    And your point is?
    Have you ever read an sec filing?
    This is standard terminology and is in virtually every company filing.
    If you don't understand what you own, I suggest you stick with a low fee S & P index fund.
    GLTA.

  • "We are pleased to demonstrate the ability of our structure-based drug design technology to identify a viable clinical candidate and the Company's ability to advance a drug from a concept into the clinic. Based on the pre-clinical safety data reported to-date, we believe CC-31244 has the potential to be a best-in-class, pan-genotypic HCV non-nucleoside inhibitor (NNI)."

  • Reply to

    Eyes have to be on.......

    by jorgewineberg Apr 29, 2016 3:51 PM
    c2crusher c2crusher May 5, 2016 8:37 PM Flag

    Cstl,
    Exactly. That's one of the Big hidden intangibles that Cocrystal has going for itself. This is not the first rodeo for all the main players here. Most are monetarily rich beyond belief. Therefore there is no need to sell prematurely or at all. Ray et al, know what they have and are committed for the long term. They know their tech and platform in the development of novel pan-genotypic therapies will be substantial. Maybe even more important for humanity than any one of us can comprehend today.
    Our biggest asset here, will be patience.
    If you believe. Be strategic. Be tactical. Be patient. And build your position over time.
    I believe the best is yet to come!
    GLTA
    Crusher

  • Reply to

    Eyes have to be on.......

    by jorgewineberg Apr 29, 2016 3:51 PM
    c2crusher c2crusher May 2, 2016 6:52 PM Flag

    Hummus,
    I, like you, have both. And am in for the long haul.
    Will continue to add too both on pull backs as long as I see progress.
    And I see a very high degree in that area for both companies.
    Patience will be rewarded.
    GLTA
    Crusher

  • Reply to

    Bridging the Sciences: Zika Virus

    by fgachille May 1, 2016 7:41 PM
    c2crusher c2crusher May 2, 2016 6:43 PM Flag

    Jorge from,
    What do we need to know about viruses?
    April 7/2016
    A bit of good news on the Zika front is that a vaccine for dengue has recently performed quite well in a small study in human volunteers. Dengue is part of the same family as Zika, and the techniques used to develop the dengue vaccine may work for a Zika vaccine as well. Both dengue and Zika are transmitted by the same mosquito, Aedes aegypti. Dengue is currently the most common mosquito-transmitted disease in the world, infecting about 400 million people world-wide. Fortunately (as with Zika) most recover and are immune to the specific dengue serotype they were infected with; however, if they should happen to be infected with a different dengue serotype, they may develop serious and potentially fatal hemorrhagic fevers.
    Cocp working on the right programs at the right time.
    Should be a very exciting time for drug discovery for innovative, best in class companies like Cocrystal trailblazing the future of first in class antivirals. CC 1845 et al
    Crusher

  • Reply to

    Eyes have to be on.......

    by jorgewineberg Apr 29, 2016 3:51 PM
    c2crusher c2crusher Apr 29, 2016 11:26 PM Flag

    Fgachille,
    Time line for completion of phase 1 is in determinant at this point. They will progress as fast as they can and as slow as they have to.
    And I didn't say they they will be merged with Opk. They may or may not be. It's my belief that there will be some relationship and it could take many forms.
    Like opk's hgh deal with Pfizer. Outright buyout or any relationship in between. I just believe they will always be connected in some way.
    Anyway you cut it both companies will be Hugh successes.
    All my opinion only.
    Crusher

  • Reply to

    Eyes have to be on.......

    by jorgewineberg Apr 29, 2016 3:51 PM
    c2crusher c2crusher Apr 29, 2016 7:41 PM Flag

    Gilead needs the pipeline and is flush with cash.
    They are very acquisitive and believe me are very aware of what Ray represents and what he is working on. They would lock him down now if they could. But that's why Ray got as much as he did from Phil cuz when the time is right those drugs will be sold under Opk label. One way or another.
    P.F. Is assembling a veritable powerhouse!
    Success belongs to those that see opportunity before it becomes obvious.
    Crusher.

  • c2crusher c2crusher Apr 28, 2016 8:01 PM Flag

    Yes it does!
    Accumulating from the 4's and will continue to add when finances permit.
    GLTA.
    Crusher

  • c2crusher c2crusher Apr 28, 2016 7:01 PM Flag

    Thanks Burn.
    Picked up another 1k today at near low of the day.
    Loving it!
    Crusher

  • Reply to

    Great news today...

    by jorgewineberg Apr 25, 2016 9:27 PM
    c2crusher c2crusher Apr 25, 2016 11:05 PM Flag

    CC-31244, an investigational pan-genotypic NNI, was developed using the Company's structure-based drug design technology.
    World class!
    This technology will produce mind blowing novel anti virals that will change the world and save lives.
    Ray's finest!
    And everything monetary Ray makes from Cocrystal will be donated to his charities!
    He's working to change people's lives for the better. Altruism at its core.
    Ray and every member of Team Cocrystal I salute you!
    Keep up the fantastic work. The way to many, wait patiently in quiet desperation.
    The world needs your future discoveries sooner than anyone here can imagine.
    God speed!
    Crusher

  • Reply to

    Great news today...

    by jorgewineberg Apr 25, 2016 9:27 PM
    c2crusher c2crusher Apr 25, 2016 10:25 PM Flag

    I am delighted to see the first compound based on the Cocrystal Discovery Platform
    One word, POWERFUL,

  • Reply to

    News about CC-31244

    by oextrader2002 Apr 25, 2016 8:20 AM
    c2crusher c2crusher Apr 25, 2016 1:59 PM Flag

    Excellent news!

  • Reply to

    What do we need to know about viruses?

    by c2crusher Apr 12, 2016 10:23 AM
    c2crusher c2crusher Apr 12, 2016 11:20 AM Flag

    ocrystal currently has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, the Human Rhinovirus (HRV), Dengue Virus, and the Norovirus. The Hepatitis C Virus is the cause of 170 million chronic infections worldwide and had a $6 billion market for treatment in 2012 that is projected to grow to $20 billion by 2020. The Company is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. The Company's Influenza, HRV, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals.

  • April 7/2016
    A bit of good news on the Zika front is that a vaccine for dengue has recently performed quite well in a small study in human volunteers. Dengue is part of the same family as Zika, and the techniques used to develop the dengue vaccine may work for a Zika vaccine as well. Both dengue and Zika are transmitted by the same mosquito, Aedes aegypti. Dengue is currently the most common mosquito-transmitted disease in the world, infecting about 400 million people world-wide. Fortunately (as with Zika) most recover and are immune to the specific dengue serotype they were infected with; however, if they should happen to be infected with a different dengue serotype, they may develop serious and potentially fatal hemorrhagic fevers.
    Cocp working on the right programs at the right time.
    Should be a very exciting time for drug discovery for innovative, best in class companies like Cocrystal trailblazing the future of first in class antivirals.
    Crusher

OPK
10.30+0.25(+2.49%)10:28 AMEDT